MANNKIND CORP Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
MANNKIND CORP (MNKD) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$14.52 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- MANNKIND CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$14.52M, a 476.21% decline from fiscal 2024.
- MANNKIND CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $3.86M, a 43.30% decline from fiscal 2023.
- MANNKIND CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $6.81M.
- MANNKIND CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$9.94M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$14.52M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $3.86M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $6.81M 10-K · filed 2026-02-26 | -$6.80M 10-K · filed 2024-02-27 |
| 2022-12-31 | -$9.94M 10-K · filed 2025-02-26 | |
| 2021-12-31 | -$19.63M 10-K · filed 2024-02-27 | |
| 2020-12-31 | -$4.85M 10-K · filed 2023-02-23 | |
| 2019-12-31 | -$5.25M 10-K · filed 2021-02-25 | |
| 2018-12-31 | -$11.07M 10-K · filed 2020-02-25 | $11.10M 10-K · filed 2019-02-26 |
| 2017-12-31 | -$260.20M 10-K · filed 2019-02-26 | |
| 2016-12-31 | -$48.10M 10-K · filed 2018-02-27 | |
| 2015-12-31 | $80.10M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $65.50M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $66.80M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $60.70M 10-K · filed 2015-03-02 | |
| 2011-12-31 | $57.20M 10-K · filed 2014-03-03 | |
| 2010-12-31 | $56.50M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |